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Abstract
Background Cancer cachexia is a poorly understood metabolic consequence of cancer. During cachexia, different adipose
depots demonstrate differential wasting rates. Animal models suggest adipose tissue may be a key driver of muscle wasting
through fat–muscle crosstalk, but human studies in this area are lacking. We performed global gene expression profiling of
visceral (VAT) and subcutaneous (SAT) adipose from weight stable and cachectic cancer patients and healthy controls.
Methods Cachexia was defined as >2% weight loss plus low computed tomography-muscularity. Biopsies of SAT and VAT
were taken from patients undergoing resection for oesophago-gastric cancer, and healthy controls (n = 16 and 8 respectively).
RNA was isolated and reverse transcribed. cDNA was hybridised to the Affymetrix Clariom S microarray and data analysed
using R/Bioconductor. Differential expression of genes was assessed using empirical Bayes and moderated-t-statistic ap-
proaches. Category enrichment analysis was used with a tissue-specific background to examine the biological context of dif-
ferentially expressed genes. Selected differentially regulated genes were validated by qPCR. Enzyme-linked immunosorbent
assay (ELISA) for intelectin-1 was performed on all VAT samples. The previously-described cohort plus 12 additional patients
from each group also had plasma I = intelectin-1 ELISA carried out.
Results In VAT vs. SAT comparisons, there were 2101, 1722, and 1659 significantly regulated genes in the cachectic, weight
stable, and control groups, respectively. There were 2200 significantly regulated genes from VAT in cachectic patients com-
pared with controls. Genes involving inflammation were enriched in cancer and control VAT vs. SAT, although different genes
contributed to enrichment in each group. Energy metabolism, fat browning (e.g. uncoupling protein 1), and adipogenesis
genes were down-regulated in cancer VAT (P = 0.043, P = 5.4 × 106 and P = 1 × 106 respectively). The gene showing the
largest difference in expression was ITLN1, the gene that encodes for intelectin-1 (false discovery rate-corrected P =
0.0001), a novel adipocytokine associated with weight loss in other contexts.
Conclusions SAT and VAT have unique gene expression signatures in cancer and cachexia. VAT is metabolically active in can-
cer, and intelectin-1 may be a target for therapeutic manipulation. VAT may play a fundamental role in cachexia, but the
down-regulation of energy metabolism genes implies a limited role for fat browning in cachectic patients, in contrast to
pre-clinical models.
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Introduction
Cachexia is a complex metabolic syndrome associated with
several chronic diseases, including cancer, that is character-
ised by loss of lean and adipose tissue1. Cachexia is a major
burden for cancer patients, and it impacts negatively on their
response to treatment, their quality of life, and survival.
Although the consensus definition of cancer cachexia2
emphasises loss of lean tissue (particularly skeletal muscle)
as a key factor in the diagnosis of the condition, the loss of
adipose tissue in cancer cachexia is increasingly thought to
play an important role.3,4
In cancer, the loss of adipose tissue is driven by lipolysis5
rather than adipocyte apoptosis or necrosis. Mediators of
lipolysis in cancer cachexia (CC) are largely unknown. In the
past, members of our group have identified increased mRNA
expression of zinc-α2-glycoprotein (ZAG), a proposed lipid
mobilizing factor, in fat samples from CC patients; however,
serum ZAG levels were unchanged from controls.6,7 Microar-
ray analysis has revealed that changes in the transcriptome of
subcutaneous fat in CC are opposite to those seen in obesity,
underlining the importance of lipolysis.8 Visceral adipose tis-
sue is thought to be lost more rapidly than subcutaneous ad-
ipose tissue during cachexia, suggesting differential adipose
depot-dependent responses to the wasting process though
this has not been consistently demonstrated in humans.9 Bio-
informatic analysis of mRNA expression in visceral (omental)
and subcutaneous adipose depots in noncachectic, obese en-
dometrial cancer patients demonstrated 19 shared biological
pathways, 18 of which were regulated in opposite directions
between the fat depots.10 Recently, focus has concentrated
on the concept of ‘fat–muscle crosstalk’ in CC.1 Notably, ge-
netic ablation of lipolytic pathways in adipocytes protects
against muscle mass loss in animal models of CC.11 Inhibition
of lipolysis through genetic ablation of adipose triglyceride li-
pase or hormone sensitive lipase was shown to reduce mus-
cle wasting.11 These data support the loss of visceral fat
driven by lipolytic mechanisms as an early event in CC with
a potential effect on skeletal muscle.
Global gene expression profiling is an effective method to
examine regulatory pathways in patho-physiological con-
texts.12 In our previous studies, microarray analysis of skeletal
muscle biopsies taken at the time of resectional surgery for
upper gastrointestinal (GI) cancer revealed an 83-gene
signature that was able to identify patients with >5% weight
loss.13 In further studies, a transcriptomic comparison of
sequential muscle biopsies (at surgery and 8 months post-
surgery) from upper GI cancer patients revealed 1868
regulated genes associated with cancer and weight loss.14
Contrary to expectation, the vast majority (94%) of genes
were down-regulated. Category analysis of the differentially
expressed genes showed that both anabolic and catabolic
process gene expression was suppressed in cancer. Further-
more, there was a lack of substantive overlap with
transcriptomic signatures from endurance training, strength
training, ageing, or simple dieting. Highly enriched categories
included lipid oxidation, fatty acid metabolism, and peroxi-
some pathways, implying a role for fat–muscle crosstalk in
CC.14 A better understanding of the physiological effects of
cancer on adipose tissue might open new therapeutic ave-
nues for the amelioration of both fat and skeletal muscle
wasting resulting in improved outcomes.
In the current study, we examined the global transcrip-
tome of VAT and SAT depots in patients with confirmed CC,
according to the diagnostic consensus definition [>2% weight
loss and low muscularity on a computed tomography (CT)
scan; n = 8] compared with weight stable cancer (CWS)
patients (n = 8), as well as healthy controls undergoing donor
nephrectomy (n = 8). These data provide the first examina-
tion of global gene expression in these two fat depots in CC
and provide a basis for hypothesis generation and exploring
treatments for CC.
Methods
Study participants
Patients undergoing surgical resection with curative intent for
upper GI cancer (oesophageal, gastric, or pancreatic) were
recruited via the regional multidisciplinary team meeting.
Healthy controls undergoing surgery for renal transplant
donation were approached at their pre-assessment appoint-
ment. Participants had to be over the age of 18 and able to
give written, informed consent. The study was approved by
the Lothian regional ethics committee (IRAS ID: 190214) and
conformed to the declaration of Helsinki. Control and CWS
patients were excluded if they were found to be sarcopenic
on CT scan. Patient demographics are described in terms of
median (interquartile range). A Kruskal Wallis test was used
to compare groups.
Adipose tissue biopsies
Following surgical skin incision under general anaesthesia,
biopsies of subcutaneous fat were taken from all patients at
the start of the operation. Visceral fat was sampled from
the greater omentum in cancer patients and perinephric fat
from the transplant donors after the kidney had been
excised. All samples were snap frozen in liquid nitrogen and
stored at 80°C until analysis.
Plasma samples
Venous blood samples were taken at induction of anaesthesia
from all patients. Samples were centrifuged at 4°C at 15 000 g
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for 15min. Plasma was then withdrawn and divided into 1mL
aliquots and frozen at 80°C until use.
Muscle cross-sectional area
Skeletal muscle, visceral, and subcutaneous adipose
cross-sectional areas were calculated from routine staging
CT scans performed prior to any surgical intervention or neo-
adjuvant chemotherapy. Digitally stored CT images com-
pleted with a spiral CT were analysed using slice-O-matic
and ABACS software (Voronoi Health Analytics, Canada).
The cross-sectional area for muscle, visceral, and subcutane-
ous adipose tissue was normalized for stature (cm2/m2) at
the level of the third lumbar vertebrae [skeletal muscle index
(SMI), visceral adipose index, and subcutaneous adipose in-
dex, respectively]. SMI cut-offs for low muscularity were
taken from previous reference studies of cancer patients by
Martin et al.15 Cachexia was classified according to the con-
sensus definition by Fearon et al. (specifically >2% weight
loss with low muscularity).2 This specific definition of CC
was used as it was shown to be associated with confirmed
histological muscle fibre wasting in our previous studies.16
Transcriptomic analysis
Aliquots of adipose tissue were homogenised in a Qiazol re-
agent (Qiagen, UK) using the BeadBeater instrument with
1.5 mm ceramic beads (Qiagen, UK). Tissue aliquots were
shaken at 5000 Hz for 30 s with 30 s cooling on ice. This pro-
cess was repeated three times or until no gross debris was
visible. Samples were then spun at 2800 g for 15 mins at 4°
C and the supernatant collected into fresh Eppendorf tubes.
RNA was isolated from adipose tissue samples using the
Qiagen RNeasy lipid tissue kit (Qiagen, UK) following the man-
ufacturer’s directions. RNA was quantified using the Denovix
DS11 FX+ spectrophotometer (Denovix, UK). RNA quality was
examined using the RNA iQ assay and the Qubit 4 instrument
(Thermo Fisher, UK). All samples returned quality scores ≥7.7.
Complementary DNA was generated using the GeneChip WT
Plus Reagent kit (Thermo Fisher, UK) as per directions. Sam-
ples were hybridised to the Clariom S GeneChip microarray
(Thermo Fisher, UK) as per manufacturers directions. After
washing and staining, images were captured, and CEL files
generated using the GeneChip Scanner 3000 (Thermofisher
UK). The raw CEL files can be accessed at the Gene Expression
Omnibus (GSE131835).
Quantitative polymerase chain reaction
Total RNA was extracted as above, and cDNA was prepared
using the High Capacity cDNA Reverse Transcription kit (Ap-
plied Biosystems, cat no. 4368814) with 500 ng total RNA
input for each reaction. Quantitative PCR (qPCR) was carried
out using Luminaris Hi Green Low ROX qPCR Master Mix
(Thermo Fisher UK, Cat no. K0974) 5 μL, 0.3 μL forward and
reverse primer at 10 μm each and 3.4 μL ddH2O. Primers
were selected from the Primer Bank resource17 except for ac-
tin beta and GAPDH. These latter primers were designed to
span exons using the Primer-BLAST resource.18 We selected
primers to cover genes involved in inflammation (ACVR2A1,
IL6, and IL18), adipogenesis (LEPR, STAT5A, and PDCD4), adi-
pose browning (UCP1, PPARGC1A, and PRDM16) as well as
genes that demonstrated a substantial statistically significant
fold change by microarray data (ITLN1, ALOX15, and PPARA).
We also profiled five genes to use as reference values in PCR
data normalization as recommended by the MIQE guide-
lines.19 PCR reactions were carried out on the LightCycler
480 Instrument with the following protocol; 50°C 2mins (ura-
cil–DNA–glycosylase treatment), 95°C 10 min (DNA denatur-
ation) and 40 cycles of 95°C 15 s and 60°C 60s before a
final melting curve step. Samples were run in triplicate on
384-well plates. Analysis of qPCR data was carried out using
the NormqPCR package in R/Bioconductor.20 The geNorm
method21 was used to identify the four most stable control
genes from actin beta, GAPDH, YWHAZ, POLR2A, and PSMB2,
and the geometric mean of these was used to normalise the
cycle threshold values for the remaining genes. Relative gene
expression was calculated using the delta–delta Cq method
(14). Primers used are shown in the Supporting Information.
Enzyme-linked immunosorbent assay
Intelectin-1 (Itln1) concentration was assessed in the VAT and
plasma using an enzyme-linked immunosorbent assay
[(ELISA) (Amsbio EH0564); sensitivity <46.875 pg/mL; refer-
ence range: 78.125–5000 pg/mL]. A further 36 patients were
recruited to increase the total of plasma samples to 20 for
each group. Plasma was diluted to a 1 to 10 concentration
and assayed in duplicates according to the manufacturer’s in-
structions. Intra-assay and interassay coefficients of variation
were <8 and <10%, respectively.
Tissue ELISA was carried out on homogenised VAT tissue.
Adipose tissue was homogenised in RIPA buffer with added
protease inhibitors (Thermo Fisher, UK). Tissue aliquots were
added to 1.5 mL PowerBead tubes with 1.4 mm ceramic
beads (Qiagen cat no 13113) and shaken at 5000 r.p.m. for
20 s with 10 s rest on ice three times using the MagNALyser
instrument (Roche, UK). The homogenate was centrifuged at
5000 r.p.m. for 15 min at 4°C, and the aqueous phase be-
neath the lipid cake and above the cell pellet was removed
to a separate tube. Aliquots were diluted 1:20 in PBS and pro-
tein content quantified using the Qubit 4 Protein Assay
(Thermo Fisher). The same ELISA kit was used for VAT and
plasma (Amsbio EH0564).
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Statistical analysis
The microarray data were analysed using R/Bioconductor
using an updated chip definition file from the Brainarray re-
source22 based on Ensembl gene definitions (ENSG version
22). Raw microarray data were normalized and filtered using
the SCAN-UPC method.23 Expression intensity and UPC filters
were set at 0 and 0.5 respectively. Use of these filters sug-
gested 49% of the genes with probes in the microarray chip
definition file were not expressed in adipose tissue. This is
in line with our previous experience using Affymterix
GeneChip microarrays. Filtering also improved the clustering
of samples by principle components analysis (Figure 1).
Changes in differential expression were examined using em-
pirical Bayes and a moderated t statistic implemented in the
limma package24 with subject identifier as a blocking factor
in linear modelling to account for the repeated measures
structure (see section Additive Models and Blocking in the
limma manual). Statistical significance was taken as a false
discovery rate <5%. Category enrichment analysis was car-
ried out using the camera algorithm25 and the Broad Institute
curated Hallmark Genesets collection.26 A false discovery rate
<5% was taken to indicate significant enrichment of a
category.
The qPCR data were analysed using the R/Bioconductor
NormqPCR package.20 The expression data was modelled
with a mixed effects linear model using the lme4 R pack-
age27 with group, fat depot, and the interaction between
these as fixed factors and subject identifier as a random
factor to account for pairing. Post hoc testing of interaction
or main effects was carried out using the emmeans28
package.
Itln1 concentrations were calculated from raw ELISA data
in R using the nCal package.29 After subtraction of blank
values as recommended by the kit manufacturer a 5-PL
model was fit to the data and concentrations back
calculated. Statistical analysis was carried out on log trans-
formed data. Tissue ELISA data were analysed using a linear
model with log Itln1 concentration modelled by group. For
the plasma ELISA data, the log Itln1 concentrations from
Assays 1 and 2 were combined and modelled with a
mixed effects model using the lme4 package27 with assay
as a random factor. Post hoc testing was carried out
using the emmeans package.28 Statistical significance was
set at P ≤ 0.05.
Results
Patient characteristics
Twenty-four patients were included in the study with eight
subjects in each of the control, CWS, and CC groups. Patient
demographics and anthropometric details are shown in Table
1. Median weight loss was significantly higher (12.5%, inter-
quartile ratio 6.87–15.5, P< 0.001), and SMI was significantly
lower in the CC group (P = 0.002). Control patients were
younger (median 51 years compared with 60 in the CWS
group and 70 in the CC group, P = 0.002). Final pathology
results for all patients can be seen in the Supporting
Information.
Microarray analysis
Filtering the microarray data as recommended by the
SCAN-UPC authors23 led to the identification of 8679
probesets (approximately 49%) as unlikely to be expressed
in adipose tissue. These were removed from the data set
prior to further analysis to improve statistical power. Principle
components analysis indicated a substantive difference in
VAT vs. SAT transcriptome profiles in the presence of cancer
Figure 1 Scatterplots showing separation of adipose depot and group samples by principle components analysis. Before (A) and after (B) removal of
non/low expressed genes using the Universal exPression Code (UPC) (Piccolo, 2013) generated filter. CC, cancer cachexia; Ctrl, healthy control; CWS,
cancer weight stable.
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(Figure 1). We first examined mRNA expression differences
between the SAT and VAT depots within each group. In the
CC group, we found 2101 probesets significantly regulated
between the fat depots with fold changes ranging from
eight-fold up-regulated to two-fold down-regulated. In the
CWS group, we found 1722 probesets significantly regulated
with fold changes ranging from nine-fold up-regulated to
2.5-fold down-regulated. In the control group, we found
1659 probesets differentially regulated with fold changes
from 4.6-fold up-regulated to 2.3-fold down-regulated. These
data indicate that SAT and VAT depots have substantial
mRNA expression differences. In addition, the number of dif-
ferentially expressed probesets is higher in the cancer groups
and highest in the CC group (table 2). Comparing VAT be-
tween the groups, we found 2200 probesets regulated (10-
fold up to 2.3-fold down) between CC and CWS, and 1253
probesets regulated (nine-fold up to 2.3-fold down) between
CC and control. No probesets met the statistical cut-off for
significance in VAT between the CC and CWS groups. ITLN1,
the gene which encodes for the novel adipocytokine Itln1,
was the most up-regulated gene with a 10-fold increase in
CC vs. control and a nine-fold increase in CWS vs. control
(Figure 2). Intelectin-2 was also significantly increased in
these comparisons. SAT demonstrated no significant differ-
ences in any comparison between CC, CWS, and control. Full
details of regulated mRNA are available in the Supporting In-
formation. These data demonstrate that whilst the transcrip-
tional profile of SAT is not sensitive to the presence of cancer
or CC in our cohort, there are substantial differences in VAT
mRNA expression in the presence of cancer.
Geneset enrichment analysis
We used the Broad Institute Hallmark-curated genesets col-
lection (17) to examine the data for geneset enrichment.
These data are summarised in Table 3 and presented in full
in the Supporting Information. We first assessed differences
between fat depots in each group (Table 3). Only Adipogen-
esis and Fatty Acid metabolism were significantly enriched in
all interdepot (VAT compared with SAT) comparisons. In can-
cer, these genesets were down-regulated in VAT compared
with SAT whilst in the control group the opposite pattern
was observed, and they were up-regulated in VAT compared
with SAT (Table 3). The Inflammatory response category was
increased in expression in both CC and control VAT com-
pared with SAT, but different genes drove the enrichment
signal in each group (Figure 3). These data suggest a
down-regulation in genes related to growth of adipose tissue
in cancer irrespective of weight loss whilst (compared with
SAT) inflammation is increased in the VAT of CC patients.
We next examined category enrichment in VAT between
the groups (Supporting Information). In both CC and CWS
VAT, the Adipogenesis and Xenobiotic metabolism (genes
encoding proteins involved in the processing of drugs)
genesets were decreased in expression compared with con-
trol VAT (Table 3). Oxidative phosphorylation was signifi-
cantly down-regulated in the VAT of CC patients compared
with that of controls but was not enriched in the comparison
of CWS vs. control VAT (Table 3).
Table 1 Demographic and selected clinical data for study subjects
Group (n = 8) Control Cachexia Weight stable P value
Male:Female 4:4 5:3 6:2 /
Age (years) 51 (48–55) 70 (64–77) 60 (57–64) 0.002
BMI 25.5 (23.75–28.25) 24 (20.25–29.25) 31.5 (23–40) 0.227
%weight loss 0 12.5 (6.87–15.5) 0 <0.001
SMI 48.30 (44.32–53.88) 39.99 (38.24–41.13) 55.52 (48.40–64.22) 0.002
VATI 20.97 (11.05–43.06) 23.3 (5.82–38.76) 55.52 (48.40–64.22) 0.196
SATI 50.32 (29.46–63.43) 50.75 (20.15–98.77) 70.35 (34.04–120.67) 0.605
OACC:OSCC:GACC N/A 6:0:2 6:1:1
Median (Interquartile range) values are presented.
BMI, body mass index; SMI, skeletal muscle index; VATI, Visceral adipose index; SATI, Subcutaneous adipose index
Table 2 Number of genes regulated in the microarray data with FDR <
5% in each within and between group comparison
No. regulated genes (FDR < 5%)
VAT vs. SAT in group comparison
CC VAT vs. SAT 2101
CWS VAT vs. SAT 1722
Control VAT vs. SAT 1659
VAT between group comparisons
CC vs. control 2200
CWS vs. control 1253
CC vs. cWS 0a
SAT between group comparisons
CC vs. Control 0b
CWS vs. Control 0c
CC vs. CWS 0d
CC, cancer cachexia; CWS, cancer weight stable; FDR, false discov-
ery rate; SAT, subcutaneous adipose tissue; VAT, visceral adipose
tissue.
alowest adjusted P value = 0.7
blowest adjusted P value = 0.1
clowest adjusted P value = 1
dlowest adjusted P value = 0.5.
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Given our observation of a down-regulated energy metab-
olism signature in the VAT of cancer patients, we specifically
examined the Gene Ontology category Brown Fat Cell Differ-
entiation (GO:0045444) and found this down-regulated in
VAT in CC (P = 5.4 × 106) and in CWS (P = 2 × 107) com-
pared with control VAT. These data suggest that there is a
down-regulation of mRNA related to adipose expansion and
energy use/generation in the VAT of cancer patients and that
there is a stronger signature in cachectic cancer patients. We
found no evidence of brown fat cell differentiation in this co-
hort of cachectic cancer patients.
Quantitative polymerase chain reaction gene
validation
We used qPCR to examine selected genes including those de-
tected as regulated in the microarray data and the biological
processes of fat browning, inflammation, and adipogenesis.
Microarray candidates
There was a significant depot by group interaction effect for
ITLN1 (P = 0.0006), the gene that encodes for Itln1. ITLN1
was significantly increased in the VAT of the cancer groups
(CC P = 0.0001, CWS P = 0.02) compared with VAT in the con-
trol group but was not different between the cancer groups
(P = 0.5). ITLN1 expression was also significantly greater in
VAT compared with SAT in the cancer groups (CC P =
0.0004, CWS P = 0.03) with no difference in the control group
(P = 0.9). There were no significant differences in ITLN1 in SAT
in any comparison. ALOX15 (a gene that encodes enzymes
which act on various polyunsaturated fatty acid substrates)
demonstrated a significant depot by group interaction effect
(P = 0.005) with increased expression in VAT in the cancer
groups compared with control (CC P = 0.018 and CWS P =
0.025, respectively). ALOX15 was increased in VAT compared
with SAT in the cancer groups (weight stable P = 0.04, cachec-
tic P = 0.0046) but not in the control group (P = 0.9). These
results are in agreement with the microarray results. PPARA2
also demonstrated a depot by group interaction (P = 0.004).
However multiple testing was unable to detect specific differ-
ences. Inspection of the qPCR data suggests lower expression
in the VAT of the cancer groups. The direction of change in
the qPCR data for the cancer groups reflected the microarray
data. PPARA2 expression between the VAT and SAT depot in
the control group was significantly different (P = 0.03).
Figure 2 Intelectin-1 mRNA expression values (log2 transformed) from the microarray data. CC, cancer cachexia; Ctrl, healthy controls; CWS, cancer
weight stable. a = significantly different from paired subcutaneous values; b = significantly different from control visceral values.
Table 3 Summary of geneset enrichment analysis
Comparison Geneset Direction FDR
Cachexia VAT
vs. SAT
Adipogenesis Down 2 × 109
Fatty Acid
Metabolism
Down 0.004
Cancer VAT
vs. SAT
Adipogenesis Down 1 × 106
Fatty Acid
Metabolism
Down 0.043
Control VAT
vs. SAT
Adipogenesis Up 1.1 × 106
Fatty Acid
Metabolism
Up 4 × 108
Cachexia VAT
vs. control
VAT
Oxidative
Phosphorylation
Down 1.24 × 1016
Adipogenesis Down 1.24 × 1016
Fatty Acid
Metabolism
Down 3.33 × 109
Xenobiotic
Metabolism
Down 0.004
Cancer VAT
vs. control
VAT
Adipogenesis Down 0.038
Xenobiotic
Metabolism
Down 0.046
Cachexia VAT
vs. cancer VAT
Adipogenesis Down 0.038
Xenobiotic
Metabolism
Down 0.046
FDR, false discovery rate; SAT, subcutaneous adipose tissue; VAT,
visceral adipose tissue.
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Genes involved in fat browning
There were no differences in UCP1 expression in terms of ei-
ther a depot by group interaction or main effects in agree-
ment with the microarray results. PPARGC1A demonstrated
a main effect of depot (P = 0.003) with VAT showing higher
expression than SAT. Post hoc testing revealed that
PPARGC1A was significantly up-regulated in the VAT com-
pared with SAT in the control group only (P = 0.01). The direc-
tion of change for PPARGC1A in other comparisons was the
same as seen in the microarray data but not statistically sig-
nificant after multiple testing correction. There were no sig-
nificant differences in PR/SET domain 16 expression in any
comparison.
Inflammation
There were no significant differences in ACVR2A1 expression
in terms of interactions or main effects, but the direction of
changes seen in the qPCR data agreed with the microarray
data. There were no significant differences in IL6 expression
in terms of interactions or main effects. IL6 was significantly
down-regulated in CC compared with control VAT in the mi-
croarray data. The direction of change was the same in the
qPCR data driven by few patients (Figure 4) and not statisti-
cally significant. IL18 demonstrated a significant depot by
group interaction effect (P = 0.0009) with increased expres-
sion in the VAT of both cancer groups compared with control
(CWS P = 0.02, CC P = 0.0001). Expression of IL18 was also in-
creased in the VAT compared with the SAT in the cancer
groups (CWS P = 0.03, CC P = 0.0006) but not in the control
group (P = 0.9).
Adipogenesis
LEPR demonstrated a significant depot by group interaction
effect (P = 0.03) with post hoc testing revealing decreased ex-
pression in the VAT in the CC compared with control group (P
= 0.04). LEPR was also increased in control VAT compared
with SAT (P = 0.02). STAT5A did not demonstrate any signifi-
cant interaction or main effects although the effect of fat de-
pot was borderline significant (P = 0.06) with specific
differences undetectable by post hoc testing. Programmed
cell death 4 did not demonstrate any significant interaction
or main effects.
ELISA results
VAT Itln1 concentrations are shown in Figure 5. Linear
modelling of log Itln1 concentration by group showed a
significant effect of the group (P = 0.04). There was a
significant difference between the CC and control groups
(mean Itln1 concentrations 43.6 ng/mL and 20.5 ng/mL
respectively, P = 0.014) but no statistically significant differ-
ence between CWS (mean Itln1 concentration 30.9 ng/mL)
and either of the other two groups.
Given that Itln1 was raised in the VAT of CC patients, we
wanted to investigate if it was also raised in the circulating
fraction of these patients, and so, plasma ELISA was under-
taken. Patients demographics of those included in the
Figure 3 Heatmap of genes in Hallmark Inflammatory Response geneset in subcutaneous and visceral adipose tissue of healthy control (Ctrl), cancer
weight stable (CWS), and cachectic cancer (CC) patients. The purple boxes delineate inflammatory genes differentially contributing to geneset enrich-
ment in cancer cachexia and controls. The cancer weight stable group demonstrate a similar signal to the cancer cachexia group but the geneset as a
whole did not meet statistical significance for enrichment in VAT versus SAT.
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plasma ELISA study are summarised in Table 4a,b4b. Plasma
Itln1 concentrations are shown in Figure 6. Mixed effects
linear modelling with group as a fixed effect and assay
run as a random effect was used to model log Itln1 con-
centrations. There was a significant effect of group (P =
0.028). Post hoc testing using Tukey’s correction demon-
strated a significant difference in plasma Itln1 concentra-
tions between the CC and CWS groups (mean Itln1
concentrations 2.6 ng/mL and 1.9 ng/mL respectively, P =
0.02). There was no significant difference between the con-
trol group (mean Itln1 concentration 2.3 ng/mL) and either
of the other groups.
Discussion
Different mechanisms have been previously proposed to ac-
count for the changes in adipose tissue seen in cachexia. In
Figure 4 Data from qPCR of selected genes. Categories of genes validated by qPCR were significantly different in microarray data (ALOX15, ITLN1, and
PPARA2), involved in browning (PPARGC1A, PRDM16, and UCP1), inflammation related (ACVR2A1, IL6, and IL18), involved in adipogenesis (LEPR,
STAT5A, and PDCD4). * = significant group × depot interaction; † = no significant interaction but significant difference between same depot in control
group. See main text for full reporting of statistically significant differences. AU, arbitrary units; CC, cancer cachexia; Ctrl, healthy controls; CWS, cancer
weight stable.
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CC, human and animal studies have shown increased rates of
lipid mobilisation and loss of adipose tissue before any de-
monstrable changes in loss of muscle mass.30 An increased
rate of adipose tissue loss has also been associated with
worsening prognosis in cancer patients highlighting the im-
portance of gaining a greater understanding of the mecha-
nisms involved. To the best of our knowledge, this is the
first study to examine both SAT and VAT depots in CC
Figure 5 Intelectin-1 visceral adipose tissue protein concentration (nanogram per millilitre) as measured by enzyme-linked immunosorbent assay
across the control (Ctrl), cancer weight stable (CWS) and cancer cachexia (CC) groups. * = significant effect of group; † = significantly different from
control group.
Table 4a Demographic details of total patients included in the ITLN-1 plasma enzyme-linked immunosorbent assay (ELISA). This cohort includes pa-
tients recruited for both array and ELISA studies
Group
(n = 20
per group) Control Cachexia
Weight
stable P value
Male:Female 14:6 14:6 14:6 /
Age (years) 49 (11) 69 (10) 64 (9) <0.001
BMI 25.66 (2.81) 25.06 (4.85) 29.93 (7.79) 0.187
%weight loss 0 11.60 (6.58) 0.26 (0.71) <0.001
SMI 50.69 (7.55) 41.54 (4.82) 55.92 (12.48) <0.001
VATI 26.23 (20.04) 41.50 (36.65) 111.90 (215.25) 0.008
SATI 52.98 (27.79) 71.85 (59.75) 71.87 (43.75) 0.460
Data are mean (SD).
BMI, body mass index; SATI, subcutaneous adipose index; SMI, skeletal muscle index, VATI, visceral adipose index.
Table 4b Demographic details of additional patients recruited the ITLN-1 plasma enzyme-linked immunosorbent assay. Excludes those patients re-
cruited to the microarray study
Group (n = 12) Control Cachexia Weight stable P value
Male:Female 10:2 9:3 8:4 /
Age (years) 48 (14) 69 (10) 68 (10) <0.001
BMI 25.77 (2.67) 25.35 (3.68) 29.05 (7.61) 0.697
%weight loss 0 11.21 (6.78) 0.43 (0.90) <0.001
SMI 51.42 (7.97) 42.56 (4.84) 56.04 (14.74) 0.019
VATI 23.65 (15.11) 51.41 (40.68) 151.78 (279.69) 0.016
SATI 51.24 (19.89) 74.69 (60.69) 69.77 (45.06) 0.620
BMI, body mass index; SATI, subcutaneous adipose index; SMI, skeletal muscle index, VATI, visceral adipose index.
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patients. We have shown that SAT and VAT have unique gene
expression signatures, and VAT has an altered gene expres-
sion signature in cancer. We found increased expression of
Itln1 and Intelectin-2 in particular suggesting these adipo-
kines may play a role in adipose changes in response to can-
cer. Itln1 may be a target for therapeutic manipulation.
The gene which showed the largest difference in expres-
sion was ITLN1; a 34 kDa novel adipokine. Expression of
ITLN2 was also high but not as great as ITLN1 and so ITLN1
formed the focus of our study. ITLN1 is preferentially pro-
duced by stromovascular cells in VAT31 but has also been
identified in human epicardial fat cells, mesothelial cells,
airway goblet cells, and cells lining the gut and ovaries.32
A series of studies have linked raised levels of ITLN1 to var-
ious cancers.33–40 ITLN1 has been suggested to promote
cancer cell growth by triggering genomic instability via
phosphatidylinositol-3 kinase downstream effector signalling
pathways.41 The role of ITLN1 in CC however, has not been
well characterised. Randomized control trials have shown
that weight loss significantly increases plasma ITLN1 con-
centration42 whereas hyper-insulinaemic induction in
healthy individuals reduces ITLN1 plasma concentration.43
Decreased levels of ITLN1 have been associated with obe-
sity in patients with ovarian cancer,43 and levels of ITLN1
measured before patients were diagnosed with colorectal
cancer have been confined to nonobese individuals suggest-
ing it has a role in weight loss.44
Our microarray results confirmed that expression of
ITLN1 was higher in VAT in cancer although not confined
to CC patients. Plasma levels of Itln1 were significantly in-
creased in CC compared with CWS groups but showed no
difference with controls suggesting it possibly has a role
in cancer induced weight loss. However, as in the previous
studies, we found that plasma Itln1 differences were driven
by a few individuals with high levels. High interindividual
variability in plasma ITLN1 likely limited the ability to detect
a statistically significant effect across all patient groups.
Larger patient studies will be required in the future to as-
certain any true difference in circulating ITLN1 in cancer.
The significant increase in intelectin seen in the VAT ELISA
of cachectic patients suggests a possible role in the patho-
genesis of cachexia. There was a clear increasing gradient
from controls through CWS to CC in VAT Itln1 level. This
was not reflected in the plasma Itln1 protein levels. These
results are similar to those we have previously seen with
zinc a-glycoprotein [ZAG]6 in CC. This pattern of increased
tissue protein levels but no change in circulating levels
could be explained by cells outside adipose tissue contrib-
uting to circulating protein. Alternatively, there could be a
predominantly paracrine role for adipose tissue secreted
protein that is not released into the circulation.
We found no evidence of increased browning in white
adipose tissue in our cohort. Previously increased thermo-
genic activity of brown and beige adipose tissue has been
shown to contribute to the increased energy expenditure
and weight loss in rodent models of cachexia.45–47 White
adipose tissue browning is associated with increased ex-
pression of UCP1, which uncouples mitochondrial respira-
tion towards thermogenesis instead of adenosine
triphosphate synthesis, leading to increased lipid mobiliza-
tion and energy expenditure.48 Whilst browning of white
fat depots contributes to futile energy cycling in cachexia
in animal models the importance of this is uncertain.49,50
Genes involved in fat browning in the present study were
Figure 6 Intelectin-1 plasma protein concentration (ng/ml) as measured by enzyme-linked immunosorbent assay across the control (Ctrl), cancer
weight stable (CWS) and cancer cachexia (CC) groups. * = significant effect of group; ‡ = significantly different from Ca group.
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not up-regulated suggesting browning has a limited role in
the pathogenesis of cachexia in the recruited patients and
highlights the importance of patient-based research. These
data provide the basis for future studies that further exam-
ine the role of adipose biology in the metabolic effects of
cancer in humans.
Cachexia is thought to be a chronic inflammatory state,
and changes in inflammatory mediators in adipocytes may
be capable of inducing changes in adipose tissue homeosta-
sis.51 Several studies have shown adipose tissue to be the tar-
get of several pro-cachectic factors as well as adipose tissue
itself being an important source of inflammatory media-
tors.52–56 The majority of studies assessing inflammation in
cachexia have examined inflammatory markers from a sys-
temic point of view rather than a tissue-specific one with
IL6 in particular frequently found to be raised in the plasma
of CC patients.57 IL6 was down-regulated in adipose tissue
in CC suggesting a possible homeostatic response. Specific ad-
ipose tissue inflammation is important to consider as it may
be an event very early on in the cachectic process prior to
any systemic effects being demonstrated.
Adipogenesis is the process by which preadipocytes dif-
ferentiate into mature adipocytes able to store triglycerides
and secrete adipokines. Some studies have shown that
adipogenic genes are down-regulated in animal epididymal
and retroperitoneal fat in cachexia.54,58 Co-culture studies
have demonstrated inhibition of pre-adipocyte maturation
in the presence of tumour cells that was associated with in-
creased inflammatory cytokines.59 Changes in adipogenesis
are likely to precede the clinical signs of fat wasting and tis-
sue inflammation. It is possible therefore that factors such
as increased infiltration of macrophages and production of
inflammatory cytokines silence adipogenic genes and/or in-
crease lipolysis leading to adipose wasting in cachexia.
The current study confers similar limitations to other mi-
croarray studies most notably in the small sample size.
However exploratory work of this nature is valuable as it
provides testable hypotheses to be taken forward. Another
limitation of this study was the availability of omental and
perinephric adipose tissue in the cancer and control groups,
respectively. Differences in these two depots are not well
defined. In rodents, there are possible depot-specific differ-
ences in innervation, but this has not been documented in
humans.60 A very small study in humans has suggested
blood flow in omental fat may be higher than in
perinephric fat though the difference was not significant.61
This may potentially the affect removal of lipolytic products
and the rates of lipolysis. The patients studied were pre-
dominantly male, and we are therefore unable to draw
conclusions about sex-specific differences. There was no
longitudinal follow-up of patients done, and so, it is unclear
whether the patients in the CWS group went on to develop
cachexia and therefore may have been pre-cachectic at the
time of biopsy. We also excluded patients in the control
and CWS groups who were sarcopenic on CT scan. In doing
so, we have assumed that a reduction in SMI in the cachec-
tic group was because of disease. Given that these patients
have a median age of 70, it is possible that some were
sarcopenic prior to the start of the disease process. We
chose to define patients based on this specific definition
of cancer cachexia (>2% weight loss and low muscularity)
as it is the previous definition that has been associated
with histological wasting.16 Notably, all but one of the par-
ticipants in our study defined as having cancer cachexia had
>5% weight loss (over 6 months). Reanalysis of the ITLN1
qPCR data after removal of this single subject did not affect
the conclusions of that analysis.
Conclusions
This exploratory analysis confirms differential gene expres-
sion in adipose depots in patients with cancer with and with-
out cachexia and highlights the importance of VAT in cancer.
VAT may have a fundamental role in cachexia, but the
down-regulation of energy metabolism genes implies a lim-
ited role for browning in cachectic patients in our cohort as
suggested in pre-clinical models. Future mechanistic studies
are important to evaluate the effects of VAT in cachexia
and in particular the role of Itln1.
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